MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Gynecologic Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

915 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
915 works in the cohort · of 4,299,418page 16 of 19

Labels cover 0 of 915 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 915 of 915 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Response to Maneo et al.
Marie Plante, Michel Roy, K. Swenerton
2006· article· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
TroFuse-020/GOG-3101/ENGOT-cx20: A phase III, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-line treatment for recurrent or metastatic cervical cancer
Ritu Salani, Kristina Lindemann, Shin Nishio, Ana Oaknin, Jean Emmanuel Kurtz, Giorgio Valabrega +18 more
2025· article· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Treatment of low-risk GTN with biweekly actinomycin-D
Clare J. Reade, Umm E Habiba, Lua Eiriksson, Marilena Cesari, Raymond Osborne
2014· article· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Predicting histologic upgrading in endometrial cancer
Emad Matanes, Cristina Mitric, Michel D. Wissing, Zainab Amajoud, Jeremie Abitbol, Neta Eisenberg +7 more
2020· article· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Management of cervical cancer in low-resource settings
L. Chuang, Gillian Thomas, Fredric V. Price, B. E. Miller, Wui‐Jin Koh, L. Perez +3 more
2012· article· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Discussion: Somatic Genetics and Signaling/Genomics/Proteomics
Sir Walter Bodmer, Edison Liu, J.W. Gray, Karen D. Rodland, David Roy Smith, Benjamin K. Tsang +1 more
2003· article· en· Gynecologic Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About